Form 4 Tracker
Aurinia Pharmaceuticals Inc.
AUPH

12 insider filings · Latest: Mar 6, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
May 11, 2026May 11 8:11 PMPETER GREENLEAF
Proposed Sale
3,136,201$15.84$49.7M

View →

May 11, 2026May 11 8:10 PMMATTHEW MAXWELL DONLEY
Proposed Sale
717,688$15.84$11.4M

View →

May 11, 2026May 11 8:07 PMJOSEPH MILLER
Proposed Sale
500,503$15.84$7.9M

View →

Mar 3, 2026Mar 3 10:35 PMKevin TangDirector
Purchase
184,208$14.22$2.6M12,229,500(I)

View →

Mar 2, 2026Mar 3 10:35 PMKevin TangDirector
Purchase
199,353$14.26$2.8M12,045,292(I)

View →

Feb 27, 2026Mar 3 10:35 PMKevin TangDirector
Purchase
516,439$13.99$7.2M11,845,939(I)

View →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Feb 27, 2026Mar 3 9:14 PMJoseph M MillerChief Financial Officer
Grant/Award
95,700$13.9795,700(D)

View →

Feb 27, 2026Mar 3 9:14 PMMatthew Maxwell DonleyChief Operating Officer
Grant/Award
97,256$13.9797,256(D)

View →

Feb 27, 2026Mar 3 9:13 PMPeter GreenleafDirector, Chief Executive Officer
Grant/Award
328,424$13.97328,424(D)

View →

Feb 27, 2026Mar 3 9:13 PMGreg KeenanSVP, Chief Medical Officer
Grant/Award
67,870$13.9767,870(D)

View →

Feb 27, 2026Mar 3 9:12 PMStephen P. RobertsonEVP, General Counsel
Grant/Award
98,813$13.9798,813(D)

View →